BiotechTube

Winlevi (clascoterone) 1% cream

ApprovedCompleted
2 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Acne Vulgaris

Conditions

Acne Vulgaris

Trial Timeline

Feb 29, 2024 → Feb 18, 2025

NCT ID
NCT06415279

About Winlevi (clascoterone) 1% cream

Winlevi (clascoterone) 1% cream is a approved stage product being developed by Sun Pharmaceutical for Acne Vulgaris. The current trial status is completed. This product is registered under clinical trial identifier NCT06415279. Target conditions include Acne Vulgaris.

What happened to similar drugs?

20 of 20 similar drugs in Acne Vulgaris were approved

Approved (20) Terminated (0) Active (0)
✅IsotretinoinSun PharmaceuticalApproved
✅Winlevi (Clascoterone) cream 1%Sun PharmaceuticalApproved
✅Winlevi (clascoterone) 1% & Duac gelSun PharmaceuticalApproved
✅Winlevi (clascoterone) 1% creamSun PharmaceuticalApproved
✅Winlevi (clascoterone) 1% creamSun PharmaceuticalApproved
✅Winlevi (clascoterone) 1% & Adapalene 0.3% gelSun PharmaceuticalApproved
✅Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiolJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06415279ApprovedCompleted
NCT06415292ApprovedCompleted
NCT06415305ApprovedCompleted

Competing Products

20 competing products in Acne Vulgaris

See all competitors
ProductCompanyStageHype Score
DFD-03Dr. Reddy's LaboratoriesPhase 3
37
Tazarotene Lotion, 0.1% + Tazarotene Cream, 0.1%Dr. Reddy's LaboratoriesPhase 2
32
DFD-03 Lotion, 0.1% + Tazorac Cream, 0.1% + DFD-03 Vehicle Lotion 0% + Tazorac Vehicle Cream 0%Dr. Reddy's LaboratoriesPhase 2
32
DFD-03 (0.1% tazarotene) Lotion + DFD-03 (0% tazarotene) Lotion (Placebo)Dr. Reddy's LaboratoriesPhase 3
37
Olumacostat Glasaretil Gel, 5.0%Eli LillyPhase 3
40
HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001 PlaceboHoth TherapeuticsPhase 2
32
Trifarotene Cream 0.005% + AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG + AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT + PlaceboSun PharmaceuticalPhase 1
29
Tretinoin Gel Microsphere, 0.1% + RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1% + Placebo ControlSun PharmaceuticalPhase 1
29
Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% + Acanya® Gel, 1.2%/2.5% + Vehicle of test productSun PharmaceuticalPhase 1
29
Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel + Duac® Topical Gel + Placebo Topical GelSun PharmaceuticalPhase 1
29
Adapalene Gel 0.1% + Placebo Control + Differin® Gel (Adapalene 0.1%, Galderma)Sun PharmaceuticalPhase 1
29
Trifarotene Cream 0.005% + Placebo + AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories)Sun PharmaceuticalPhase 1
29
Adapalene/BP gel, 0.3%/2.5% + EPIDUO® FORTE + PlaceboSun PharmaceuticalPhase 1
29
ADPS topical product + Placebo ControlSun PharmaceuticalPhase 2
35
IsotretinoinSun PharmaceuticalApproved
43
Winlevi (Clascoterone) cream 1%Sun PharmaceuticalApproved
47
Adapalene Gel 0.3% + Differin® + PlaceboSun PharmaceuticalPhase 1
29
CLPG Topical Gel 1% + Clindamycin + PlaceboSun PharmaceuticalPhase 1
29
Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% + Epiduo® Gel + PlaceboSun PharmaceuticalPhase 1
29
Test. + Aczone Gel 5% + PlaceboSun PharmaceuticalPhase 1
29